XEN-D0101

XEN-D0101 is an experimental drug that was developed to treat atrial fibrillation.

Uses your system voice; voice and rate in settings.

≈ 2 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

XEN-D0101 is an experimental drug that was developed to treat atrial fibrillation. Xention, a biopharmaceutical company based in Cambridge, England, created XEN-D0101 along with other ion channel-modulating drugs. XEN-D0101 is a selective antagonist of the voltage-gated potassium channel Kv1.5. Atrial fibrillation is the main focus of Xention’s drug development, as it is the most common cardiac arrhythmia (irregular heart beat) seen in patients.

Atrial fibrillation

Atrial fibrillation (AF) is an arrhythmia that occurs in 1-2% of the general population. AF is linked to several cardiac causes including hypertension and coronary artery disease, and AF increases the risk for stroke. Current strategies to manage AF are effective but many are associated with adverse side effects.

Due to the irregular rhythm occurring in the atria, targeting them with antiarrhythmic drugs without affecting the ventricles would provide a desirable outcome.

Mechanism of action

A recognized atrial selective drug target is Kv1.5, which is found in atria but not in ventricles. Kv1.5 carries the ultra rapid delayed rectifier current known as Ikur. In a normal heart, the atria depolarize and repolarize in a very organized fashion.

During atrial fibrillation, this process becomes chaotic and the atrial depolarization occurs faster than it should causing the irregular heart beat and impaired atrial contraction. XEN-D0101 is a Kv1.5 antagonist that selectively prolongs the atrial refractory period. By prolonging the refractory period XEN-D0101 allows the atria to fully relax and not contract prematurely.

XEN-D0101 selectively increases atrial refractory period by 22% in dogs with atrial tachycardia induced electrical remodeling. XEN-D0101 differs from other AF drugs in that it doesn’t effect ventricular contraction, as determined by assessing the QT interval on an echocardiogram.

The QT interval represents ventricular depolarization and repolarization, and XEN-D0101 did not significantly increase the timing of this interval. UNII_Ref = UNII = 2S9KS24SYB

Text derived from https://en.wikipedia.org/w/index.php?oldid=1361792795 under CC BY-SA 4.0; modifications have been made.

Words in each sectionMechanism of actionMechanism of actionMechanism of action: 181 words181Atrial fibrillationAtrial fibrillationAtrial fibrillation: 72 words72
Words in each section. Measured from the stored article body; sections below the minimum are not plotted.

Provenance

snapshot enwiki-001361792795 · captured 2026-06-30 · ledger · version history

Cite this page as: encyclopegia.org, “XEN-D0101”, snapshot enwiki-001361792795. https://encyclopegia.org/a/xen-d0101

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.